About Henlius-Management Team

Wenjie Zhang

Chief Executive Officer
President

Mr. Wenjie Zhang is Executive Director, Chief Executive Officer and President of Shanghai Henlius Biotech, Inc.

Mr. Zhang has 25 years of commercial experience in the pharmaceutical industry. Before joining Henlius in March 2019, he was the Executive Director, Marketing for Amgen Japan and Asia Pacific region at first and then being promoted as General Manager of Amgen China where he was leading company’s overall efforts in expanding business into Chinese market and help Chinese patients to access Amgen’s innovative medicines. During his tenure as General Manager, Amgen China has effectively built up its commercial infrastructure, organization, and competency. He successfully launched Repatha^® (evolocumab), Amgen’s first product in China. Prior to Amgen, Mr. Zhang worked as Vice President, Oncology for Roche in Shanghai, China, where he was managing a strong team of 850 sales and marketing staff in the oncology franchise marketing business unit. He significantly grew the Roche oncology portfolio including Avastin^® (bevacizumab), Tarceva^®(erlotinib) and MABTHERA^® (rituximab) in the China market. He also led Roche China oncology franchise in pipeline planning, franchise strategy, and franchise marketing. Before then, Mr. Zhang served as the head of Business Development at Bayer Schering Pharma, Asia Pacific Headquarters, Product Manager of US Marketing, Business Development Manager and Deputy Director of Global Marketing at Bayer Pharmaceuticals USA. In this role, he led the fastest growing business unit within Bayer China. He also had dual responsibility as Head of the same business unit for Asia Pacific region. He succeeded in launching multiple products in China including Nexavar, Kogenate and Betaferon. Mr. Zhang obtained his MBA from the Yale University School of Management in 1998. He graduated with a B.S. in microbiology from Shandong University in Jinan, China in 1990.
James Guo

SVP
Secretary of the Board

Mr. James Guo, Senior Vice President and Secretary of the Board, graduated from Genetics and Genetic Engineering Department of Fudan University, and holds a MBA degree from Zhejiang University. He has previously served as research manager, vice president and chief engineer in Hangzhou Jiuyuan Gene Engineering Co., Ltd., Hangzhou Taishi Biotechnology Co., Ltd., Zhejiang Cifu Pharmaceutical Co. and Shanghai Chemo Wanbang Biopharma Co., Ltd. James is experienced in biopharmaceutical development and production, and familiar with all types of national laws and regulations. He has been involved in the development of a Category II new drug which is the first listed recombinant human granulocyte colony-stimulating factor (rhG-CSF) injection in China. He was awarded Outstanding Technology Development Talent of Hangzhou, Second Prize for Science and Technology Progress Award of Zhejiang Province and First Prize for Science and Technology Progress Award of Hangzhou. In addition, he is the vice-chairman of Shanghai Biopharmaceutics Industry Association Monoclonal Antibody Drug Professional Committee currently.
Wei Huang

Chief Operation Officer
SVP

Ms. Wei Huang, Chief Operation Officer and Senior Vice President, responsible for commercialized production and delivery, and construction of Songjiang Site. Ms. Huang holds Bachelor degree from East China University of Science and Technology in Biochemical Engineering, Master degree from University of Maryland in Chemical and Biochemical Engineering. Prior to joining Henlius, Ms. Huang has Senior management and leadership experience in pharmaceutical and biotechnology industry spanning over twenty-five years in process development, technology transfer, manufacturing, process and facility design, capital project execution, and quality system implementation.
Jason Zhu

Chief Medical Officer
SVP

Mr. Jason Zhu, Chief Medical Officer and Senior Vice President, responsible for whole Global Product Development team. Jason has more than 17 years in clinical research industry. He had cooperated with over 70 China local pharmaceutical and biotech companies and led the design and execution of over 100 phase I to IV clinical trials. Prior to joining Henlius, Jason was Founder and CEO of PPC China, Global Vice President of IQVIA, China GM of Omnicare. Jason had previously worked as a physician in Huashan Hospital for two years. Jason holds a bachelor degree in Clinical Medicine form Shanghai Medical College of Fudan University and an EMBA degree from CKGSB.
Simon Hsu

Chief Technology Officer
SVP

Dr. Simon Hsu, Chief Technology Officer and Senior Vice President, holds Ph.D. degree from Purdue University in Biochemical Engineering, Master degree from Ohio State University in Biochemical Engineering, and Bachelor degree from National Tsing Hua University in Chemical Engineering. Prior to joining Henlius, Simon has 24 years of management and research experience in the pharmaceutical industry. He has served as CMC Executive Director and Head of CMC and Quality in Pieris Pharmaceuticals, Director-CMC and External Drug Substance Manufacturing in Shire, Technical Director, Biologics External Manufacturing in Bristol-Myers Squibb, Associate Director, Head of Process Biochemistry and CMC Team Lead, in MedImmune, and Principle Scientist of Process Development in Alexion Pharmaceuticals. He has rich experience in quality management, CMC project management, IND and NDA filing, CMO management, global pre-clinical through commercialized product supply, process development and technology transfer etc.
Wenfeng Xu

SVP of US Research

Dr. Wenfeng Xu, Senior Vice President of US Research, responsible for research strategy and pipeline of innovative products. Dr. Xu has 25 years of biopharmaceutical R&D experience, serving leadership roles such as Principal Scientist at ZymoGenetics, Director of Molecular Immunology at Novo Nordisk, and Associate Director of Bioanalytical Science for Cancer Immunotherapy at Genentech. He started his biotech career focusing on the novel protein identification, molecular annotation and immune functional study. Then he built a team for target validation and clinical trial support in the area of autoimmune diseases, and later provided bioanalytical and biomarker assays for immunotherapy clinical development. Dr. Xu received his bachelor’s degree in Biochemistry at Fudan University, Ph.D. degree in Molecular Biology from Shanghai Institute of Biochemistry, Chinese Academy of Science, postdoctoral training at University of Washington in Seattle, and the First Prize Award of Natural Science from Chinese Academy of Science in 1998.
Ningshu Liu

SVP

Dr. Ningshu Liu, Senior Vice President of Henlius. Dr. Ningshu Liu holds Ph.D. degree from University of Marburg (Germany) in Human Medicine, Master degree from Tokyo University (Japan) in Biochemistry and Molecular Biology, and Bachelor degree from Peking University (China) in Physiology and Biophysics. Prior to joining Henlius, Dr. Ningshu Liu has over 20 years of research and development experience in the pharmaceutical industry, has served as Research Fellow, Sr. Director-Global Strategy Lead, Head of Laboratory Immuno-Oncology, Head of Laboratory Oncogenic Signaling in Bayer Germany, Group leader of Oncology Research in Bayer Research Center USA, Group Manager of Asthma and Inflammation diseases in Bayer Research Center Kyoto, etc. Dr. Ningshu Liu has extensive experience in the field of immune-oncology drug development.
Gino Li

Chief Financial Officer
VP

Mr. Gino Li, Chief Financial Officer and Vice President, is responsible for listing investment management, market value management and financial operation management. Previously, Mr. Li served as vice president and the general manager of investor relations and capital development department of Fosun Pharma. Mr. Li obtained a Bachelor of Science degree in Pharmacy from Sichuan University in 2004, a Master of Science degree from the University of Huddersfield in the U.K. in 2006, and a master’s degree from the IMBA Programme of Fudan University – Hong Kong University in 2016.
Ping Cao

VP of Business Development

Ms. Ping Cao, Vice President of Business Development, graduated from Tianjin University with a BS in Material Science & Engineering and MS in Chemical Engineering and also obtained her MS in Organic Chemistry at Michigan State University. She previously worked at Tyger Scientific, Ferro,Bristol-Myer Squibb (BMS) and Abzena, and held positions of Director of Sales and Marketing, Sr. Manager of Business Development, Associate Director of Global Manufacturing and Supply Chain, and Sr. Director of Business Development. At Tyger Scientific, Ms. Cao increased the business revenue 600% in 4 years. At BMS, she was responsible for global business development at CMO (contract manufacture operation) and accomplished significant sales growth. Then Ms. Cao joined business development team focusing on technology transactions. She negotiated and executed 36 technology collaboration deals to expedite the company’s drug discovery and development process. As a reward for her accomplishment, Ms. Cao received the Distinguished Employee Award, Innovation Award etc. at BMS. At Abzena, she developed and executed the business strategy of offering integrated contract manufacture service of biologics and antibody drug conjugates based on company core technologies of antibody drug conjugation and humanization, which greatly enhanced the company’s business growth worldwide.
Kurt Yu

VP of Marketing and Commercial Operation

Mr. Kurt Yu, Vice President of Marketing and Commercial Operation, leads the marketing team and is responsible for the marketing strategy development, new product launch preparation, marketing activity planning and execution. He also takes charge of product pricing, market access and distribution management. Prior to joining Henlius, Mr. Yu has over 20 years’ experience in sales and central marketing management (for Glaxo Wellcome, Roche and Amgen) with different roles including medical representative, product manager, district sales manager, marketing manager, and marketing director/ head. He has rich experience in portfolio management, marketing strategy development, new product launch etc.

Mr. Yu graduated from Shanghai Medical University with bachelor degree in pharmaceutical chemistry. Then he obtained the EMBA degree from Fudan University.
Wallis Zeng

VP of Sales

Mr. Wallis Zeng, Vice President of Sales, graduated from Gannan Medical University, majoring in clinical medicine.

Mr. Zeng is responsible for the sales strategy development, establishing and leading the sales team to achieve the annual sales targets. Prior to joining Henlius, he served as regional sales manager at MSD, national sales director at Roche, general manager at Evergrande Health and sales director at AZ. So far, he has about 30 years’ working experience. Mr. Zeng has rich experience in sales strategy development and sales team management.